Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop-Reference-Cited by-同舟云学术

Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop

Published:2020-01 Issue:1 Volume:203 Page:115-119
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Weinstock Chana¹,Suzman Daniel¹,Kluetz Paul¹,Baxley John¹,Viviano Charles¹,Ibrahim Amna¹,Jarow Jonathan¹,Sridhara Raejshwari¹,Liu Ke¹,Carroll Peter²,Eggener Scott³,Hu Jim C.⁴,Hussain Maha⁵,King Martin⁶,Klein Eric⁷,Kungel Terry⁸,Makarov Danil⁹,Pinto Peter A.¹⁰,Rini Brian⁷,Roach Mack²,Sandler Howard¹¹,Schlegel Peter N.¹²,Song Daniel¹³,Goldberg Kirsten¹,Pazdur Richard¹,Beaver Julia A.¹

Affiliation:

1. United States Food and Drug Administration, Silver Spring, Maryland

2. University of California-San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California

3. University of Chicago Medicine, Chicago, Illinois

4. Weill Cornell Medicine, New York, New York

5. Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine, Chicago, Illinois

6. Dana Farber Cancer Institute, Harvard Medical Center, Boston, Massachusetts

7. Cleveland Clinic, Cleveland, Ohio

8. Maine Coalition to Fight Prostate Cancer, Augusta, Maine

9. New York University School of Medicine, New York, New York

10. National Cancer Institute, Bethesda, Maryland

11. Cedars-Sinai Medical Center, Los Angeles, California